Pregled bibliografske jedinice broj: 1275973
PARP inhibitors in ovarian cancer treatment
PARP inhibitors in ovarian cancer treatment // Libri Oncologici
Opatija, Hrvatska, 2017. str. 19-19 (predavanje, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1275973 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
PARP inhibitors in ovarian cancer treatment
Autori
Silovski, Tajana
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Libri Oncologici
/ - , 2017, 19-19
Skup
1st Regional Congress of Medical Oncology and 1st Regional Congress of Oncology Pharmacy Croatian Society for Medical Oncology, Croatian Medical Association Oncology Pharmacy Session, Croatian Pharmaceutical Society
Mjesto i datum
Opatija, Hrvatska, 04.05.2017. - 07.05.2017
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Ovarian cancer treatment, PARP inhibitors
Sažetak
PARP inhibitors represent targeted therapy in ovarian cancer treatment. They are specifi cally active in cells that have impaired repair of DNA by the homologous recombination (HR) pathway. Cells with mutated BRCA have HR defi ciency which is also present in a signifi cant proportion of non-BRCA- mutated ovarian cancer. High-grade ovarian cancers are more often platinum sensitive and moreover have the most underlying defects in DNA repair. Furthermore, patients with high-grade, platinum sensitive ovarian cancers may also benefi t from PARP inhibitors irrespective of BRCA status. Second-generation studies are investigating the combination of PARP inhibitors with anti- angiogenic, immuno-oncology and DNA-repair inhibiting agents.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
